X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2126) 2126
Publication (171) 171
Newsletter (39) 39
Book Review (21) 21
Newspaper Article (4) 4
Book Chapter (3) 3
Magazine Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1353) 1353
male (1187) 1187
fenofibrate (1182) 1182
index medicus (857) 857
female (791) 791
fenofibrate - therapeutic use (786) 786
middle aged (733) 733
hypolipidemic agents - therapeutic use (609) 609
animals (587) 587
fenofibrate - pharmacology (553) 553
adult (491) 491
triglycerides - blood (428) 428
pharmacology & pharmacy (412) 412
aged (399) 399
hypolipidemic agents - pharmacology (380) 380
cholesterol (326) 326
rats (304) 304
lipids - blood (280) 280
fenofibrate - administration & dosage (276) 276
mice (269) 269
lipids (263) 263
cholesterol - blood (256) 256
risk factors (248) 248
cholesterol, hdl - blood (247) 247
endocrinology & metabolism (247) 247
drug therapy, combination (243) 243
hyperlipidemias - drug therapy (220) 220
cholesterol, ldl - blood (219) 219
diabetes (217) 217
treatment outcome (212) 212
atherosclerosis (210) 210
research (199) 199
cardiac & cardiovascular systems (198) 198
triglycerides (198) 198
fenofibrate - adverse effects (194) 194
dyslipidemias - drug therapy (190) 190
coronary-heart-disease (189) 189
hypolipidemic agents - administration & dosage (188) 188
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (180) 180
dyslipidemia (176) 176
statins (173) 173
metabolic syndrome (172) 172
peripheral vascular disease (172) 172
metabolism (170) 170
fibric acids (169) 169
double-blind method (166) 166
diabetes mellitus, type 2 - drug therapy (165) 165
ppar-alpha (165) 165
risk (162) 162
hypolipidemic agents - adverse effects (159) 159
atorvastatin (154) 154
hyperlipidemia (146) 146
type 2 diabetes (144) 144
inflammation (142) 142
therapy (142) 142
ppar alpha - agonists (141) 141
simvastatin (141) 141
cardiovascular-disease (140) 140
diabetes mellitus, type 2 - complications (139) 139
medicine, general & internal (139) 139
biochemistry & molecular biology (138) 138
care and treatment (135) 135
gemfibrozil (131) 131
insulin resistance (129) 129
fenofibrate - analogs & derivatives (127) 127
liver - metabolism (126) 126
expression (125) 125
drug therapy (124) 124
disease (123) 123
health aspects (123) 123
liver - drug effects (122) 122
hyperlipidemias - blood (121) 121
diabetes mellitus, type 2 - blood (120) 120
cardiovascular disease (116) 116
lipoproteins (116) 116
oxidative stress (112) 112
hypertriglyceridemia - drug therapy (110) 110
fibrates (108) 108
hypertriglyceridemia (108) 108
insulin-resistance (108) 108
lipoproteins - blood (108) 108
ppar alpha - metabolism (105) 105
dyslipidemias - blood (103) 103
medicine, research & experimental (103) 103
physiological aspects (102) 102
anticholesteremic agents - therapeutic use (101) 101
cardiovascular (100) 100
dose-response relationship, drug (100) 100
liver (100) 100
article (99) 99
blood glucose - metabolism (99) 99
type-2 diabetes-mellitus (99) 99
analysis (97) 97
biomarkers - blood (96) 96
rats, wistar (96) 96
time factors (95) 95
low density lipoproteins (94) 94
mice, inbred c57bl (93) 93
rats, sprague-dawley (93) 93
rodents (93) 93
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2028) 2028
French (36) 36
Russian (17) 17
Czech (15) 15
German (14) 14
Polish (13) 13
Spanish (13) 13
Chinese (9) 9
Japanese (8) 8
Korean (6) 6
Hungarian (3) 3
Croatian (2) 2
Romanian (2) 2
Swedish (2) 2
Turkish (2) 2
Ukrainian (2) 2
Italian (1) 1
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Toxicologic Pathology, ISSN 0192-6233, 6/2017, Volume 45, Issue 4, pp. 506 - 525
Journal Article
Diabetes, ISSN 0012-1797, 03/2003, Volume 52, Issue 3, pp. 803 - 811
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, ISSN 0946-1965, 11/2012, Volume 50, Issue 11, pp. 805 - 813
Objective: Concerns regarding worsening insulin sensitivity associated with statin treatment have recently emerged. Therefore the aim of this study was to... 
PPAR-ALPHA | proinflammatory cytokines | LEPTIN LEVELS | atorvastatin | LDL CHOLESTEROL | ADIPONECTIN RECEPTORS | INFLAMMATION | CARDIOVASCULAR-DISEASE | PHARMACOLOGY & PHARMACY | fenofibrate | adipokines | CORONARY-HEART-DISEASE | insulin resistance | ADIPOSE-TISSUE | Glucose Metabolism Disorders - immunology | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Glucose Metabolism Disorders - drug therapy | Male | Insulin - blood | Fenofibrate - therapeutic use | Adipokines - blood | Hyperlipoproteinemia Type V - drug therapy | Leptin - blood | Time Factors | Interleukin-6 - blood | Lipids - blood | Hyperlipoproteinemia Type V - diagnosis | Poland | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Hyperlipoproteinemia Type V - immunology | Cytokines - blood | Hyperlipoproteinemia Type V - blood | Risk Reduction Behavior | Inflammation Mediators - blood | Insulin Resistance | Treatment Outcome | Biomarkers - blood | Glucose Metabolism Disorders - diagnosis | Adiponectin - blood | Blood Glucose - drug effects | Atorvastatin Calcium | Analysis of Variance | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Glucose Metabolism Disorders - blood | Resistin - blood | Aged | Hypolipidemic Agents - therapeutic use | Blood Glucose - metabolism | Fenofibrate | Atorvastatin | Insulin resistance | Proinflammatory cytokines | Adipokines
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 9, p. e106993
The metabolic syndrome (MS) is characterized by insulin resistance, dyslipidemia and hypertension. It is associated with increased risk of cardiovascular... 
IMPROVES INSULIN SENSITIVITY | OXIDATIVE STRESS | ENDOTHELIAL DYSFUNCTION | FATTY LIVER-DISEASE | FENOFIBRATE | MULTIDISCIPLINARY SCIENCES | NITRIC-OXIDE | RESISTANCE | CORONARY-HEART-DISEASE | HYPERTENSIVE-RATS | DIETARY FRUCTOSE | Malondialdehyde - metabolism | Fructose - adverse effects | Rats, Wistar | Glutathione - metabolism | Cholesterol - blood | Body Weight - drug effects | Rats | Male | Metabolic Syndrome - metabolism | Insulin - blood | Metabolic Syndrome - drug therapy | Blood Glucose - drug effects | Metabolic Syndrome - blood | Ursodeoxycholic Acid - pharmacology | Fenofibrate - pharmacology | Animals | Insulin Resistance - physiology | Triglycerides - blood | Glycation End Products, Advanced - blood | Blood Pressure - drug effects | Uric Acid - blood | Nitric Oxide Synthase Type III - metabolism | Oxidative Stress - drug effects | Nitric Oxide Synthase Type II - metabolism | Drinking water | Liver | Body weight | Dyslipidemia | Elasticity | Cardiovascular disease | Leukocytes | Glucose | Blood | Antioxidants | Hepatitis | Receptors | Acid resistance | Aorta | Blood pressure | Drug dosages | Advanced glycosylation end products | Liver diseases | Glycosylation | Insulin | Nitric-oxide synthase | Malondialdehyde | Endothelium | Nutrition research | Ostomy | Pharmacy | Infiltration | Cardiovascular diseases | Metabolic disorders | Oxidative stress | Medical services | Metabolic syndrome | Tissues | Oxidation resistance | Rodents | Gastroenterology | Heart diseases | Glutathione | Hypertension | Diabetes mellitus | Health risks | Triglycerides | Pharmacology | Inflammation | Uric acid | Fructose | Cholesterol | Fenofibrate | White blood cells | Acids | Insulin resistance | Peroxisome proliferator-activated receptors | Diabetes | Bile
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 08/2007, Volume 30, Issue 8, pp. 1945 - 1951
Journal Article
Atherosclerosis, ISSN 0021-9150, 2016, Volume 247, pp. 35 - 39
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 09/2012, Volume 11, Issue 1, pp. 109 - 109
Background: Few large-scale, real-world studies have assessed the relative associations of lipid fractions with diabetic microvascular events. The main... 
ADA treatment goals | Nephropathy | Retinopathy | Lipid subfractions | Diabetes | Neuropathy | Microvascular complications | UNITED-STATES | CARDIAC & CARDIOVASCULAR SYSTEMS | HYPERLIPIDEMIA | RANDOMIZED CONTROLLED-TRIAL | DENSITY-LIPOPROTEIN CHOLESTEROL | ENDOCRINOLOGY & METABOLISM | INTERVENTION | ASSOCIATION | FENOFIBRATE THERAPY | Diabetic Neuropathies - blood | Multivariate Analysis | Diabetic Neuropathies - etiology | Diabetic Nephropathies - etiology | Humans | Middle Aged | Diabetic Angiopathies - etiology | Male | Diabetic Nephropathies - blood | Diabetic Retinopathy - physiopathology | Microcirculation | Diabetic Angiopathies - physiopathology | Lipids - blood | Adult | Cholesterol, LDL - blood | Female | Retrospective Studies | Diabetic Angiopathies - prevention & control | Diabetic Retinopathy - etiology | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Biomarkers - blood | Diabetic Angiopathies - blood | Diabetic Retinopathy - blood | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Triglycerides - blood | Cholesterol, HDL - blood | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Health insurance | Diabetic retinopathy | Codes | Statistical analysis | Disease | Laboratories | Mortality | Diabetic neuropathy | Triglycerides | Cholesterol | Confidence intervals | Lipoproteins | Health maintenance organizations--HMOs | Health Insurance Portability & Accountability Act 1996-US
Journal Article
Diabetologia, ISSN 0012-186X, 9/2010, Volume 53, Issue 9, pp. 1846 - 1855
Journal Article
Journal Article